2021
DOI: 10.1136/ejhpharm-2021-002880
|View full text |Cite
|
Sign up to set email alerts
|

Benefit versus toxicity risk of digoxin in patients with COVID-19

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 5 publications
0
1
0
Order By: Relevance
“…Beyond the medication effects, several cardiac manifestations have been described in patients with COVID-19 including acute myopericarditis, acute coronary syndrome, congested heart failure, cardiogenic shock, and cardiac arrhythmias as a result of the injuries caused by the virus and systemic inflammation [ 287 ]. These cardiac manifestations were not only shown with CQ or HCQ use, but also with other drugs used in the treatment of COVID-19 such as corticosteroids, rivabirin, LPVr, and AZM [ 288 , 289 , 290 , 291 ]. This suggests that COVID-19 could have a role in these cardiac safety reports.…”
Section: Discussionmentioning
confidence: 99%
“…Beyond the medication effects, several cardiac manifestations have been described in patients with COVID-19 including acute myopericarditis, acute coronary syndrome, congested heart failure, cardiogenic shock, and cardiac arrhythmias as a result of the injuries caused by the virus and systemic inflammation [ 287 ]. These cardiac manifestations were not only shown with CQ or HCQ use, but also with other drugs used in the treatment of COVID-19 such as corticosteroids, rivabirin, LPVr, and AZM [ 288 , 289 , 290 , 291 ]. This suggests that COVID-19 could have a role in these cardiac safety reports.…”
Section: Discussionmentioning
confidence: 99%